ID signaling pathway (WP53)
The Inhibitor of DNA binding (ID) proteins belong to the class V HLH family of transcription factors. Four ID proteins (ID 1-4)are known in humans. Unlike the basic HLH (bHLH) transcription factors, ID proteins lack the basic DNA binding region. They can heterodimerize with class I bHLH transcription factors to form inactive complexes. They thus act as dominant negative inhibitors of the class I bHLH transcription factors. They are also capable of regulating the activity of class II HLH transcription factors. Since, class I and II HLH proteins regulate the expression of cell type-specific genes and differentiated phenotype, ID proteins are thought to regulate the cross-talk between the pathways involved in cell growth and differentiation. Aberrant expression of ID proteins are found in many primary tumors and are found to regulate many steps in cancer progression including neo-angiogenesis, invasion and migration, proliferation and growth, cell-cell interaction and differentiation. These include head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, melanoma, hepatocellular carcinonoma, pancreatic cancer, ovarian cancer, cervical cancer, breast cancer and prostate cancer. Among the transcription factors that ID proteins associate with are the Ets family members (ELKs) and paired box family (PAXs). They can also bind to the retinoblastoma and retinoblastoma-like proteins (RBLs), which are thought to be tumor suppressors. IDs can also be phosphorylated by CDK2. Please access this pathway at [http://www.netpath.org/netslim/id_pathway.html NetSlim] database. If you use this pathway, please cite following paper: Kandasamy, K., Mohan, S. S., Raju, R., Keerthikumar, S., Kumar, G. S. S., Venugopal, A. K., Telikicherla, D., Navarro, J. D., Mathivanan, S., Pecquet, C., Gollapudi, S. K., Tattikota, S. G., Mohan, S., Padhukasahasram, H., Subbannayya, Y., Goel, R., Jacob, H. K. C., Zhong, J., Sekhar, R., Nanjappa, V., Balakrishnan, L., Subbaiah, R., Ramachandra, Y. L., Rahiman, B. A., Prasad, T. S. K., Lin, J., Houtman, J. C. D., Desiderio, S., Renauld, J., Constantinescu, S. N., Ohara, O., Hirano, T., Kubo, M., Singh, S., Khatri, P., Draghici, S., Bader, G. D., Sander, C., Leonard, W. J. and Pandey, A. (2010). NetPath: A public resource of curated signal transduction pathways. Genome Biology. 11:R3.
AuthorsAkhilesh Pandey , Kristina Hanspers , Martina Summer-Kutmon , Martijn Van Iersel , NetPath , Christine Chichester , Lauren J. Dupuis , Egon Willighagen , and Eric Weitz
Discuss this pathway
Check for ongoing discussions or start your own.
- Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease (2021).
- Long Term Culture of the A549 Cancer Cell Line Promotes Multilamellar Body Formation and Differentiation towards an Alveolar Type II Pneumocyte Phenotype (2016).
- Integrated Enrichment Analysis of Variants and Pathways in Genome-Wide Association Studies Indicates Central Role for IL-2 Signaling Genes in Type 1 Diabetes, and Cytokine Signaling Genes in Crohn's Disease (2013).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Pathway Ontologysignaling pathway Inhibitor of DNA binding signaling pathway
- NetPath: a public resource of curated signal transduction pathways. Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GSS, Venugopal AK, et al. Genome Biol. 2010 Jan 12;11(1):R3. PubMed Europe PMC Scholia